Insider Cluster (2 insiders) ·Filed Jun 4, 2026

HALO

HALOZYME THERAPEUTICS, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago
Insider cluster: 2 insiders, $214K total
Actionable Insight • Neutral

This insider cluster is routine and non-informative. The CEO's option exercises and same-day sales are standard cashless exercise mechanics, not a bearish signal. No action warranted; monitor for any material corporate events that could trigger more substantial insider activity.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
HALO ▲ +47.14% at T+60d
NEUTRAL call ✓ call won +47.14% · α vs SPY +45.26% · entry $71.60 → $105.35
Entry anchored
Jun 3, 2026
via day open
T+1d
-0.10%
call -0.10% · α +2.50%
$71.53
settled 4mo ago
T+5d
-1.22%
call -1.22% · α +1.34%
$70.73
settled 4mo ago
T+20d
+10.96%
call +10.96% · α +12.34%
$79.45
settled 3mo ago
T+60d
+47.14%
call +47.14% · α +45.26%
$105.35
settled 5w ago

Price Chart

Loading chart...

Executive Summary

CEO Helen Torley and a director sold a combined ~$214K in open-market shares on June 1, 2026, at ~$66/share. The CEO also exercised options at $12.07 and sold a portion of the resulting shares in a same-day same-window pattern, which is typical for tax-covering and liquidity rather than a bearish signal. The total open-market sales represent ~0.003% of HALO's $7.9B market cap — trivial and routine.

Key Financial Metrics

Direction
selling
Total Value
$214.0K
Insiders
2

Key Facts

  • CEO Helen Torley sold 1,610 shares open-market on June 1, 2026, for ~$107K.
  • Director Bernadette Connaughton sold 1,625 shares open-market on June 1, 2026, for ~$108K.
  • CEO also exercised 70,000 options at $12.07 on June 1-3, 2026, and sold a portion of the resulting shares — a routine cashless exercise pattern.
  • Total open-market sales of ~$214K represent ~0.003% of HALO's $7.9B market cap — immaterial.
  • No other insiders traded in the window; the cluster is limited to two individuals.

Financial Impact

Total open-market sales of ~$214K, or ~0.003% of market cap.

Risk Factors

  • None from this filing — the cluster is too small to be informative.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
69% bullish (16 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-HALO-1780531645955
6 reports for HALO
Performance horizon
Filters
Rows
Reports for HALO — sortable, filterable
TypeNow
Aug 20, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$106.12 $112.45▲ +5.96%▲ +5.96%$109.25 (+2.94%)
Jul 9, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$78.62 $85.76▲ +9.08%▲ +6.84%$109.25 (+38.95%)
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$79.45 $83.30▲ +4.85%▲ +5.26%$109.25 (+37.50%)
Jun 4, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$71.60 $79.45▲ +10.96%▲ +12.34%$109.25 (+52.58%)
Apr 30, 2026
22w ago
8-K
NEUTRAL ★ 3/10
$63.66 $68.18▲ +7.10%▲ +2.13%$109.25 (+71.61%)
Mar 23, 2026
27w ago
DEFA14A
NEUTRAL ★ 2/10
$62.04 $68.40▲ +10.25%▲ +1.35%$109.25 (+76.09%)
Showing 6 of 6

US Market Status

Market Open — Closes in 3h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 4, 2026